For example, as blockade of the PD-1/PD-L1 pathway becomes more widespread in cancer therapy, understanding their expression status in ICC patients can help determine which patients are most likely to benefit and enable personalized treatment. This evidence concerns the gene CD274 and intrahepatic cholangiocarcinoma.